• A government agreement reportedly grants Trump, his family, and his businesses immunity from audits as part of a broader settlement tied to a $1.8 billion compensation fund for alleged government weaponization.
  • The rollout of the fund is in doubt amid backlash and legal questions, with the administration signaling a potential pause or reevaluation.
  • Legal experts raise constitutional concerns about the immunity provision, which is unprecedented in federal practice.

Unprecedented Immunity Deal

In a development that has stunned legal observers, the government has reportedly agreed to bar audits of former President Donald Trump, his family, and his businesses as part of a broader settlement. The immunity arrangement is linked to a proposed $1.8 billion compensation fund intended to compensate individuals who allege government overreach, a package that has drawn substantial scrutiny.

The details, according to people familiar with the matter, were finalized in recent weeks but have not been publicly disclosed. The DOJ declined to comment, and representatives for Trump did not respond to requests for comment.

Fund in Limbo

By late May, reports emerged that the administration was hesitating on the fund's rollout amid a firestorm of criticism. Congressional lawmakers from both parties have questioned the legality and precedent of using taxpayer money for such a purpose, while watchdog groups have threatened lawsuits. The fund's future remains uncertain, with some insiders suggesting it may be scaled back or restructured.

“Without a clear legal framework, the fund could face significant hurdles,” said a former DOJ official familiar with settlement negotiations.

Political and Market Implications

The immunity provision has sparked debate about accountability and the separation of powers. Critics argue it sets a dangerous precedent by shielding a former president from standard oversight, while supporters frame it as protection against politicized prosecutions. Markets have taken notice: political uncertainty stemming from the deal has contributed to a slight uptick in volatility in Treasury yields, though broader indices remain stable.

“Investors are watching this closely,” said a senior analyst at a Washington-based research firm. “Any erosion of institutional norms can have long-term implications for governance risk premiums.”

What’s Next

The administration is expected to issue a formal statement in the coming weeks, but no timeline has been set. Legal challenges are likely, and Congress may hold hearings. Without a resolution, the fund—and the immunity deal—could be tied up in courts for months.

Correction: An earlier version of this article misstated the timing of the fund's announcement. It has been updated.